<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02100722</url>
  </required_header>
  <id_info>
    <org_study_id>FAME 3</org_study_id>
    <nct_id>NCT02100722</nct_id>
  </id_info>
  <brief_title>A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease</brief_title>
  <acronym>FAME 3</acronym>
  <official_title>Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 Trial A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VZW Cardiovascular Research Center Aalst</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Golden Jubilee National Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genae</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College Hospital, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Houston Methodist DeBakey Heart and Vascular Center, Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Fractional flow reserve (FFR, (coronary
      pressure wire-based index for assessing the ischemic potential of a coronary lesion)-guided
      percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease
      (CAD) will result in similar outcomes to coronary artery bypass graft surgery (CABG).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The FAME 3 trial is a multicenter, international, randomized, controlled noninferiority
      trial. All patients with multivessel CAD (not involving the left main) will be screened by
      the site's Heart Team (including but not limited to an interventional cardiologist, cardiac
      surgeon and research coordinator). If all agree that the patient can be treated either with
      FFR-guided PCI or CABG, and all inclusion criteria are met and no exclusion criteria are met,
      then the patient will be randomized.

      Baseline clinical, functional, laboratory and electrocardiographic data will be obtained.
      Patients will receive treatment within 4 weeks of randomization. Patients randomized to CABG
      will receive state of the art therapy at the discretion of the local surgeon with a strong
      emphasis on arterial revascularization. Patients undergoing PCI will have FFR measured with a
      St. Jude Medical coronary pressure wire across all lesions. If the FFR is ≤0.80, then PCI
      will be performed with the Medtronic Resolute Integrity drug-eluting stent (DES) as per usual
      routine. If the FFR is &gt;0.80 then PCI will be deferred.

      All patients will receive medical therapy as per published guidelines. Patients will
      follow-up at 1 and 6 months, and 1 and 3 years with an evaluation of clinical status,
      functional status, medications and events. Follow-up may be extended to 5 years, if funding
      allows.

      Core lab analyses will include formal quantitative coronary angiography (QCA) of the baseline
      angiograms with calculation of the Synergy between Percutaneous Coronary Intervention with
      Taxus and Cardiac Surgery (SYNTAX) score and Functional SYNTAX Score.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACCE</measure>
    <time_frame>1 year</time_frame>
    <description>Death, MI, stroke and any repeat revascularization (MACCE) will be evaluated at 1 year, where subjects contribute data from time of randomization until the occurrence of MACCE or one year follow-up, whichever occurs first. Subjects who die or are lost to follow up before 1 year will be censored at their last recorded activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death, MI, and stroke</measure>
    <time_frame>3 years</time_frame>
    <description>Death, MI, and stroke will be evaluated at 3 years, where subjects contribute data from time of enrollment until the occurrence of one of the above events or three year follow-up, whichever occurs first. Subjects who die or are lost to follow up before this time will be censored at their last recorded activity.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>MACCE</measure>
    <time_frame>2 years, 3 years, 5 years</time_frame>
    <description>Death, MI, stroke and any repeat revascularization (MACCE) rate at 2 years, 3 years and 5 years</description>
  </other_outcome>
  <other_outcome>
    <measure>Death</measure>
    <time_frame>1 year, 2years, 3 years, 5 years</time_frame>
    <description>Death will be evaluated at 1 year, 2 years, 3 years and 5 years, excluding patients lost to follow-up from each arm</description>
  </other_outcome>
  <other_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>1 year, 2 years, 3 years and 5 years</time_frame>
    <description>MI will be evaluated at 1 year, 2 years, 3 years and 5 years, excluding patients lost to follow-up from each arm</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroke</measure>
    <time_frame>1 year, 2 years, 3 years and 5 years</time_frame>
    <description>Stroke will be evaluated at 1 year, 2 years, 3 years and 5 years, excluding patients lost to follow-up from each arm</description>
  </other_outcome>
  <other_outcome>
    <measure>Repeat revascularization</measure>
    <time_frame>1 year, 2 years, 3 years and 5 years</time_frame>
    <description>Any repeat revascularization will be evaluated at 1 year, 2 years, 3 years and 5 years, excluding patients lost to follow-up from each arm</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Coronary Stenosis</condition>
  <arm_group>
    <arm_group_label>FFR guided PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergoing PCI will have FFR measured with a St. Jude Medical coronary pressure wire across all lesions. If the FFR is ≤0.80, then PCI will be performed with the Medtronic Resolute Integrity drug-eluting stent (DES) as per usual routine. If the FFR is &gt;0.80 then PCI will be deferred. Only those sites with prior experience measuring FFR will be included in the FAME 3 trial. These patients in whom FFR of a particular lesion was not possible will be included in all analyses based on the intention to treat principle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CABG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CABG will be performed as per clinical routine at each participating center. Both off-pump and on-pump surgery are acceptable, as long as the surgeon and the site are experienced in the particular technique. An internal mammary graft to the LAD should be attempted in all cases, if feasible. Complete arterial revascularization is strongly recommended, however, each center should use a conduit strategy with which they are most comfortable. All vessels ≥ 1,5 mm in diameter and with ≥ 50% stenosis should be bypassed, if technically feasible.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FFR guided PCI</intervention_name>
    <arm_group_label>FFR guided PCI</arm_group_label>
    <other_name>Fractional Flow Reserve-Guided PCI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CABG</intervention_name>
    <arm_group_label>CABG</arm_group_label>
    <other_name>Coronary Artery Bypass Graft Surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age ≥ 21 years with angina and/or evidence of myocardial ischemia

          -  2. Three vessel CAD, defined as ≥ 50% diameter stenosis by visual estimation in each
             of the three major epicardial vessels or major side branches, but not involving left
             main coronary artery, and amenable to revascularization by both PCI and CABG as
             determined by the Heart Team. Patients with a non-dominant right coronary artery may
             be included if only the left anterior descending artery (LAD) and left circumflex have
             ≥50% stenosis

          -  3. Willing and able to provide informed, written consent

        Exclusion Criteria:

          -  1. Requirement for other cardiac or non-cardiac surgical procedure (e.g., valve
             replacement, carotid revascularization)

          -  2. Cardiogenic shock and/or need for mechanical/pharmacologic hemodynamic support

          -  3. Recent STEMI (&lt;5 days prior to randomization)

          -  4. Ongoing Non STEMI with biomarkers (cardiac troponin) still rising

          -  5. Known left ventricular ejection fraction &lt;30%

          -  6. Life expectancy &lt; 2 years

          -  7. Requiring renal replacement therapy

          -  8. Undergoing evaluation for organ transplantation

          -  9. Participation or planned participation in another clinical trial, except for
             observational registries

          -  10. Pregnancy

          -  11. Inability to take dual antiplatelet therapy for six months

          -  12. Previous CABG

          -  13. Left main disease requiring revascularization

          -  14. Extremely calcified or tortuous vessels precluding FFR measurement

          -  15. Any target lesion with in-stent drug-eluting stent restenosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William F Fearon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nico HJ Pijls, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina Hospital Eindhoven, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard De Bruyne, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VZW Cardiovascular Research Center Aalst</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William F Fearon, MD</last_name>
    <phone>650-725-2621</phone>
    <email>wfearon@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frederik M Zimmermann, MD</last_name>
    <phone>0031402398360</phone>
    <email>frederik.zimmermann@cze.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Palo Alto VA</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Giacomini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-2004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William F Fearon, MD</last_name>
      <phone>650-725-2621</phone>
      <email>wfearon@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>William F Fearon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Medical Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jdow@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Kreton Mavromatis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jesse Brown VA Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>dgriza@uic.edu</email>
    </contact>
    <investigator>
      <last_name>Mladen Vidovich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Lawrence</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Tadross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lexinton VA</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Abdel-Latif, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khaled Ziada, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Lotfi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HealthEast St. Joseph's Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mudasser Ahmed, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn Presbyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>susanne.donovan@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>William H Matthai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centennial Heart</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Paul.Myers@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Paul Myers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ARShah@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Alpesh Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Ragosta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peninsula Health</name>
      <address>
        <city>Frankston</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jamie Layland, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital Melbourne</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Wilson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Concord Hospital</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andy Yong, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal North Shore</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ravinay Bhindi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Sydney</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Ng, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Center Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300 Aalst</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard de Bruyne, MD, PhD</last_name>
      <phone>003253 72 44 47</phone>
      <email>bernard.de.Bruyne@OLVZ-aalst.be</email>
    </contact>
    <investigator>
      <last_name>Bernard de Bruyne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Le'Centre Hospitalier de l'Universite de Montreal</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>caroline.vallieres.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Samer Mansour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>York PCI Group INC</name>
      <address>
        <city>Ontario</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Miner</last_name>
    </contact>
    <investigator>
      <last_name>Steve Miner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aun-Yeong Chong, MD</last_name>
      <email>achong@ottawaheart.ca</email>
    </contact>
    <investigator>
      <last_name>Aun-Yeong Chong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Masaryk University and University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jana.rutarova@cktch.cz</email>
    </contact>
    <investigator>
      <last_name>Petr Kala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Engstroem, MD</last_name>
      <email>Thomas.engstroem@rh.regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Thomas Engstroem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Hospital</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>janine.salandre@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles Rioufol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hungarian Institute of Cardiology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>piroth@freemail.hu</email>
    </contact>
    <investigator>
      <last_name>Zsolt Piroth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>sjpark@summitmd.com</email>
    </contact>
    <investigator>
      <last_name>Seung-Jung Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santariskiu Klinikos</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jurgina.vaitkiene@santa.lt</email>
    </contact>
    <investigator>
      <last_name>Giedrius Davidavicius, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nico HJ Pijls, MD, PhD</last_name>
      <phone>040-2398360</phone>
      <email>Nico.Pijls@inter.nl.net</email>
    </contact>
    <contact_backup>
      <last_name>Frederik M Zimmermann, MD</last_name>
      <phone>040-2398360</phone>
      <email>frederik.zimmermann@cze.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Nico HJ Pijls, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederik M Zimmermann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HagaZiekenhuis</name>
      <address>
        <city>The Hague</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G.J.W. Bech, M.D. PhD.</last_name>
    </contact>
    <investigator>
      <last_name>G. Jan-Willem Bech, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dick Beuving</last_name>
      <email>d.beuving@diagram-zwolle.nl</email>
    </contact>
    <investigator>
      <last_name>Jan Henk Dambrink, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Gerard.Devlin@waikatodhb.health.nz</email>
    </contact>
    <investigator>
      <last_name>Gerard Devlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alf Inge Larsen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alf Inge Larsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>iatros007@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Branko Beleslin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Sreckovic7@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nikola Jagic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Oskar Angeras</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Danderyds Sjukhus</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>hedvig.tjerneld@ds.se</email>
    </contact>
    <investigator>
      <last_name>Nikolaos Östlund Papadogeorgos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska Institutet, Dep of clinical science and education, Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>malin.an.persson@sodersjukhuset.se</email>
    </contact>
    <investigator>
      <last_name>Nils Witt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wales Heart Research Institute</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Anderson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Coventry and Warwickshire</name>
      <address>
        <city>Coventry and Warwickshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luke Tapp, MD</last_name>
      <email>ltapp@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Luke Tapp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Joanne.kelly@gjnh.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Keith G Oldroyd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>joanne.jessup@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Philip MacCarthy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olaf Wendler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Thomas' Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Redwood, MD</last_name>
    </contact>
    <investigator>
      <last_name>Simon Redwood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Jaydeep.Sarma@UHSM.NHS.UK</email>
    </contact>
    <investigator>
      <last_name>Jaydeep Sarma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospital NHS Trust</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajesh Kharabanda, MD, PhD</last_name>
      <email>Rajesh.Kharbanda@ouh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospitals NHS Trust</name>
      <address>
        <city>Southhampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Nick.Curzen@SUHT.SWEST.NHS.UK</email>
    </contact>
    <investigator>
      <last_name>Nick Curzen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Serbia</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/26386784</url>
  </link>
  <reference>
    <citation>Zimmermann FM, De Bruyne B, Pijls NH, Desai M, Oldroyd KG, Park SJ, Reardon MJ, Wendler O, Woo J, Yeung AC, Fearon WF. Rationale and design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 Trial: a comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with multivessel coronary artery disease. Am Heart J. 2015 Oct;170(4):619-626.e2. doi: 10.1016/j.ahj.2015.06.024. Epub 2015 Jul 9.</citation>
    <PMID>26386784</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2014</study_first_submitted>
  <study_first_submitted_qc>March 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2014</study_first_posted>
  <last_update_submitted>October 7, 2017</last_update_submitted>
  <last_update_submitted_qc>October 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>William Fearon</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

